Pfizer Q1 Earnings Preview: Analysts Sound Caution

Pfizer (PFE) faces headwinds from patent expirations on blockbuster drugs like Ibrance and Eliquis, as well as looming drug-pricing reforms. Investors are keen to hear management's strategies for defending its vaccine and oncology franchises and updates on the pipeline to counter the patent cliff.

Despite these challenges, Pfizer's stock may offer value. GuruFocus estimates fair value at $28.82, about 25% above recent closes. The company has a history of exceeding EPS forecasts, doing so in each of the last eight quarters, and beating revenue estimates in five of those periods.

However, analysts at Bank of America Securities and Goldman Sachs maintain Hold ratings on PFE, reflecting concerns about long-term growth and the need for greater clarity on strategic initiatives. Investors should closely monitor Pfizer's Q1 earnings call for insights into these critical areas.

Analysts expect earnings of $0.60 per share and revenue of $13.97 billion.

The Vyndaqel family of drugs, which treat a rare heart condition, is expected to drive strong growth.

Patent expirations, increasing competition, and uncertainty around long-term growth prospects.

Do you think Pfizer can overcome its challenges and deliver strong growth? Let us know!

Share this article with others who need to stay ahead of this trend!